gatifloxacin has been researched along with Disease Models, Animal in 46 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Besifloxacin is as effective as moxifloxacin and gatifloxacin in a rabbit model for topical prophylaxis and treatment of PRSP-induced endophthalmitis." | 7.76 | Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. ( Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2010) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 7.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "3% gatifloxacin drops to prevent endophthalmitis in a rabbit model." | 7.73 | Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model. ( Bartholomew, LR; de Castro, LE; Sandoval, HP; Solomon, KD; Vroman, DT, 2006) |
| "The effectiveness of oral gatifloxacin was compared to that of standard parenteral antibiotic therapy (nafcillin) for the treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in a rabbit model." | 7.71 | Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits. ( Calhoun, JH; Mader, JT; Shirtliff, ME, 2002) |
| "Osteomyelitis is an inflammatory bone disease caused by pyogenic bacteria." | 5.34 | Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. ( Baddour, MM; El-Kamel, AH, 2007) |
| "Besifloxacin is as effective as moxifloxacin and gatifloxacin in a rabbit model for topical prophylaxis and treatment of PRSP-induced endophthalmitis." | 3.76 | Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis. ( Hesje, CK; Marquart, ME; Moore, Q; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2010) |
| "Topical therapy with gatifloxacin before and after intraocular bacteria challenge led to lower incidences of endophthalmitis in rabbits." | 3.74 | Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis. ( Haugen, B; Haymore, J; Kleinmann, G; Mamalis, N; Olson, RJ; Romaniv, N; Werner, L, 2008) |
| "3% is at least as effective as ciprofloxacin at healing corneal ulcers infected with Pseudomonas aeruginosa when gatifloxacin is administered less frequently than ciprofloxacin." | 3.73 | Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. ( Carrier, M; Jensen, H; Short, B; Zerouala, C, 2005) |
| "3% gatifloxacin drops to prevent endophthalmitis in a rabbit model." | 3.73 | Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model. ( Bartholomew, LR; de Castro, LE; Sandoval, HP; Solomon, KD; Vroman, DT, 2006) |
| "The fourth-generation fluoroquinolone, gatifloxacin, is an effective prophylaxis against the development of keratitis after lamellar keratectomy in rabbits with an organism resistant to methicillin, levofloxacin, and ciprofloxacin." | 3.72 | Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. ( Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T, 2003) |
| "The efficacies of prophylactic and therapeutic gatifloxacin and moxifloxacin were assessed in a BALB/c mouse model of systemic and pneumonic plague and compared with ciprofloxacin." | 3.72 | Efficacy of the latest fluoroquinolones against experimental Yersinia pestis. ( Beedham, RJ; Brooks, TJ; Lever, MS; Russell, P; Stagg, AJ; Steward, J; Taylor, RR, 2004) |
| "The effectiveness of oral gatifloxacin was compared to that of standard parenteral antibiotic therapy (nafcillin) for the treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in a rabbit model." | 3.71 | Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits. ( Calhoun, JH; Mader, JT; Shirtliff, ME, 2002) |
| " Bactericidal activity of gatifloxacin was correlated with the area under the time-concentration curve-to-MBC ratio; maximal activity was achieved when gatifloxacin concentrations exceeded the MBC for the entire dosing interval." | 2.41 | Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. ( McCracken, GH, 2000) |
| "In vivo phototoxicity studies are important to predict drug-induced phototoxicity in humans; however, a standard methodology has not established." | 1.46 | The abdominal skin of female Sprague-Dawley rats is more sensitive than the back skin to drug-induced phototoxicity. ( Harada, Y; Kuga, K; Miyamoto, M; Miyamoto, Y; Sakai, Y; Sato, K; Shimizu, F; Takamatsu, Y; Yasuno, H, 2017) |
| "The developed system is a viable alternative to conventional eyedrops of GTN due to its ability to enhance bioavailability through its longer precorneal residence time." | 1.43 | Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel. ( Kant, S; Kesavan, K; Pandit, JK, 2016) |
| "Besifloxacin-treated eyes had significantly lower CFU recovered as compared with that of gatifloxacin- and moxifloxacin-treated eyes (P < 0." | 1.37 | Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis. ( Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A, 2011) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin, and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea." | 1.36 | Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2010) |
| "Gatifloxacin was injected subcutaneously at 100 mg/kg body weight every 8 h for 4 weeks." | 1.35 | In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. ( Daw-Garza, A; Lozano-Garza, HG; Ocampo-Candiani, J; Rocha, NC; Said-Fernández, S; Vera-Cabrera, L; Waksman de Torres, N; Welsh, O, 2008) |
| "Osteomyelitis is a difficult to treat bacterial infection of the bone." | 1.35 | Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. ( Arhin, FF; Caron, L; Delorme, D; Dietrich, E; Fadhil, I; Ferreira, SS; Houghton, TJ; Kang, T; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Rafai Far, A; Sarmiento, I; Tanaka, KS; Viens, F, 2008) |
| "Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection." | 1.35 | Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. ( Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A, 2009) |
| "Gatifloxacin was administered at 6- or 8-h intervals beginning 24 h postchallenge for 21 days, and dosing was designed to produce profiles mimicking fractionated concentration-time profiles for humans." | 1.34 | Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. ( Ambrose, PG; Bhavnani, SM; Craig, WA; Drusano, GL; Forrest, A; Heine, HS; Rubino, CM, 2007) |
| "Use the ID(50) (infectious dose to 50% of experimental animals) to quantify the most effective prophylactic dosing regimen to use with gatifloxacin 0." | 1.34 | Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. ( Friday, JW; Kleinert, LB; Nix, DE; Patula, VB; Slade, DS; Snyder, RW, 2007) |
| "Osteomyelitis is an inflammatory bone disease caused by pyogenic bacteria." | 1.34 | Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. ( Baddour, MM; El-Kamel, AH, 2007) |
| "Ertapenem is a promising new treatment for patients with pneumococcal pneumonia, including those at risk of infection with a fluoroquinolone-resistant strain." | 1.34 | Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia. ( Bast, DJ; De Azavedo, JC; Dresser, L; Duncan, CL; Low, DE; Walker, SE, 2007) |
| " Rabbits were subsequently dosed with 1 drop, 3 times per day for 4 days with either moxifloxacin, gatifloxacin, or a commercially available irrigating solution." | 1.34 | Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%. ( Hiddemen, JW; McCartney, MD; Rice, RL; Shepard, AR; Wax, MB; Williams, KK, 2007) |
| "The pharmacodynamic parameters of peak serum drug concentration/MIC (peak/MIC) ratio and the area under the curve (AUC)/MIC ratio have been used to characterize in vivo drug exposure and its relationship to bacterial killing for the fluoroquinolones." | 1.31 | Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. ( Banevicius, M; Li, D; Mattoes, HM; Nicolau, DP; Nightingale, CH; Turley, C; Xuan, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.52) | 18.2507 |
| 2000's | 35 (76.09) | 29.6817 |
| 2010's | 7 (15.22) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Griffith, ME | 1 |
| Moon, JE | 1 |
| Johnson, EN | 1 |
| Clark, KP | 1 |
| Hawley, JS | 1 |
| Hospenthal, DR | 1 |
| Murray, CK | 1 |
| Adams, DA | 1 |
| Riggs, MM | 1 |
| Donskey, CJ | 1 |
| Ambrose, PG | 1 |
| Forrest, A | 1 |
| Craig, WA | 1 |
| Rubino, CM | 1 |
| Bhavnani, SM | 1 |
| Drusano, GL | 1 |
| Heine, HS | 1 |
| Daw-Garza, A | 1 |
| Welsh, O | 1 |
| Said-Fernández, S | 1 |
| Lozano-Garza, HG | 1 |
| Waksman de Torres, N | 1 |
| Rocha, NC | 1 |
| Ocampo-Candiani, J | 1 |
| Vera-Cabrera, L | 1 |
| Tanaka, KS | 1 |
| Houghton, TJ | 1 |
| Kang, T | 1 |
| Dietrich, E | 1 |
| Delorme, D | 1 |
| Ferreira, SS | 1 |
| Caron, L | 1 |
| Viens, F | 1 |
| Arhin, FF | 1 |
| Sarmiento, I | 1 |
| Lehoux, D | 1 |
| Fadhil, I | 1 |
| Laquerre, K | 1 |
| Liu, J | 1 |
| Ostiguy, V | 1 |
| Poirier, H | 1 |
| Moeck, G | 1 |
| Parr, TR | 1 |
| Rafai Far, A | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kuga, K | 1 |
| Yasuno, H | 1 |
| Sakai, Y | 1 |
| Harada, Y | 1 |
| Shimizu, F | 1 |
| Miyamoto, Y | 1 |
| Takamatsu, Y | 1 |
| Miyamoto, M | 1 |
| Sato, K | 1 |
| Kesavan, K | 1 |
| Kant, S | 1 |
| Pandit, JK | 1 |
| Fukuda, M | 1 |
| Sasaki, H | 1 |
| Moshirfar, M | 1 |
| Chew, J | 1 |
| Werner, L | 2 |
| Meyer, JJ | 1 |
| Hunter, B | 1 |
| Stevens, S | 1 |
| Jensen, M | 1 |
| Kleinmann, G | 2 |
| Mamalis, N | 2 |
| Romanowski, EG | 3 |
| Mah, FS | 3 |
| Kowalski, RP | 3 |
| Yates, KA | 3 |
| Gordon, YJ | 3 |
| O'Callaghan, R | 1 |
| Ohnsman, C | 1 |
| Song, J | 1 |
| Sanders, ME | 4 |
| Norcross, EW | 4 |
| Moore, QC | 3 |
| Shafiee, A | 4 |
| Marquart, ME | 4 |
| Jhamb, SS | 1 |
| Singh, PP | 1 |
| Moore, Q | 1 |
| Sanfilippo, CM | 2 |
| Hesje, CK | 2 |
| Sokolova, GB | 1 |
| Maliev, BM | 1 |
| Mozhokina, GN | 1 |
| Elistratova, NA | 1 |
| Solov'eva, IP | 1 |
| Bugaenko, SE | 1 |
| Tungsiripat, T | 1 |
| Sarayba, MA | 2 |
| Kaufman, MB | 1 |
| Sweet, PM | 2 |
| Taban, M | 2 |
| Carpenter, TR | 1 |
| McDonnell, PJ | 2 |
| Shoen, CM | 1 |
| DeStefano, MS | 1 |
| Sklaney, MR | 1 |
| Monica, BJ | 1 |
| Slee, AM | 1 |
| Cynamon, MH | 1 |
| Chiba, K | 1 |
| Sugiyama, A | 1 |
| Hagiwara, T | 1 |
| Takahashi, S | 1 |
| Takasuna, K | 1 |
| Hashimoto, K | 1 |
| Hyon, JY | 1 |
| Joo, MJ | 1 |
| Hose, S | 1 |
| Sinha, D | 1 |
| Dick, JD | 1 |
| O'Brien, TP | 1 |
| Croisier, D | 1 |
| Etienne, M | 1 |
| Piroth, L | 1 |
| Bergoin, E | 1 |
| Lequeu, C | 1 |
| Portier, H | 1 |
| Chavanet, P | 1 |
| Steward, J | 2 |
| Lever, MS | 2 |
| Russell, P | 1 |
| Beedham, RJ | 1 |
| Stagg, AJ | 1 |
| Taylor, RR | 1 |
| Brooks, TJ | 2 |
| Jensen, H | 1 |
| Zerouala, C | 1 |
| Carrier, M | 1 |
| Short, B | 1 |
| Shamie, N | 1 |
| Reiser, BJ | 1 |
| Graff, JM | 1 |
| Kesler-Diaz, A | 1 |
| Osann, KE | 1 |
| Piercy, T | 1 |
| Donnenfeld, RS | 1 |
| Perry, HD | 1 |
| Solomon, R | 1 |
| Jensen, HG | 1 |
| Stein, J | 1 |
| Snyder, RW | 2 |
| Wittpenn, JR | 1 |
| Donnenfeld, ED | 1 |
| de Castro, LE | 1 |
| Sandoval, HP | 1 |
| Bartholomew, LR | 1 |
| Vroman, DT | 1 |
| Solomon, KD | 1 |
| Slade, DS | 1 |
| Friday, JW | 1 |
| Nix, DE | 1 |
| Kleinert, LB | 1 |
| Patula, VB | 1 |
| Barequet, IS | 1 |
| Habot-Wilner, Z | 1 |
| Lavinsky, F | 1 |
| Ziv, H | 1 |
| Belkin, M | 1 |
| Rosner, M | 1 |
| El-Kamel, AH | 1 |
| Baddour, MM | 1 |
| De Azavedo, JC | 1 |
| Dresser, L | 1 |
| Duncan, CL | 1 |
| Walker, SE | 1 |
| Low, DE | 1 |
| Bast, DJ | 1 |
| Williams, KK | 1 |
| Shepard, AR | 1 |
| Rice, RL | 1 |
| McCartney, MD | 1 |
| Wax, MB | 1 |
| Hiddemen, JW | 1 |
| Balzli, CL | 1 |
| McCormick, CC | 1 |
| Caballero, AR | 1 |
| Huang, B | 1 |
| Wigington, L | 1 |
| Smith, E | 1 |
| Tang, A | 1 |
| O'Callaghan, RJ | 1 |
| Wiskur, BJ | 1 |
| Robinson, ML | 1 |
| Farrand, AJ | 1 |
| Novosad, BD | 1 |
| Callegan, MC | 1 |
| Haugen, B | 1 |
| Romaniv, N | 1 |
| Haymore, J | 1 |
| Olson, RJ | 1 |
| Ishida, K | 1 |
| Kaku, M | 1 |
| Irifune, K | 1 |
| Mizukane, R | 1 |
| Takemura, H | 1 |
| Yoshida, R | 1 |
| Tanaka, H | 1 |
| Usui, T | 1 |
| Tomono, K | 1 |
| Suyama, N | 1 |
| Sato, A | 1 |
| Kitazawa, H | 1 |
| Hayakawa, H | 1 |
| Chida, K | 1 |
| Iwata, M | 1 |
| Miyashita, N | 1 |
| Niki, Y | 1 |
| Kishimoto, T | 1 |
| Nakajima, M | 1 |
| Matsushima, T | 1 |
| McCracken, GH | 1 |
| Perrig, M | 1 |
| Acosta, F | 1 |
| Cottagnoud, M | 1 |
| Gerber, CM | 1 |
| Täuber, MG | 1 |
| Cottagnoud, P | 1 |
| Mattoes, HM | 1 |
| Banevicius, M | 1 |
| Li, D | 1 |
| Turley, C | 1 |
| Xuan, D | 1 |
| Nightingale, CH | 1 |
| Nicolau, DP | 1 |
| Shirtliff, ME | 1 |
| Calhoun, JH | 1 |
| Mader, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Clinical Trial Comparing the Effect of Moxifloxacin Versus Gatifloxacin Following Pterygium Excision on Corneal Epithelial Healing and Epithelial Toxicity.[NCT00892918] | 40 participants (Anticipated) | Interventional | 2009-06-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for gatifloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Child; Disease Models, Animal; Drug Administr | 2000 |
1 trial available for gatifloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug | 2004 |
44 other studies available for gatifloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Do | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Dis | 2007 |
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Topics: Air Microbiology; Animals; Anthrax; Anti-Infective Agents; Area Under Curve; Bacillus anthracis; Dis | 2007 |
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Fluoroquinolones; Gatifl | 2008 |
Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Animals; Disease Models, Animal; Esters; Female; Fluoroquinolones; Humans; Molecular Structure; Orga | 2008 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
The abdominal skin of female Sprague-Dawley rats is more sensitive than the back skin to drug-induced phototoxicity.
Topics: Abdomen; Administration, Oral; Animals; Back; Dermatitis, Phototoxic; Disease Models, Animal; Doxycy | 2017 |
Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel.
Topics: Alginates; Animals; Anti-Bacterial Agents; Biological Availability; Carboxymethylcellulose Sodium; C | 2016 |
Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing.
Topics: Animals; Anti-Bacterial Agents; Cell Proliferation; Cell Survival; Corneal Injuries; Disease Models, | 2015 |
Comparison of the effects of fourth-generation fluoroquinolones on corneal re-epithelialization in rabbit eyes.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Corn | 2008 |
Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis.
Topics: Animals; Anti-Bacterial Agents; Benzalkonium Compounds; Corneal Stroma; Disease Models, Animal; Drug | 2008 |
Laboratory data and statistical evidence in fluoroquinolone study.
Topics: Administration, Topical; Animals; Anterior Chamber; Anti-Infective Agents; Collagen; Colony Count, M | 2008 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2009 |
A short-term model for preliminary screening of potential anti-tubercular compounds.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Discovery; Fem | 2009 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2010 |
Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2010 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Micr | 2011 |
[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Drug Tolera | 2011 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Mode | 2003 |
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Topics: Administration, Oral; Animals; Aza Compounds; Blood Pressure; Chloralose; Disease Models, Animal; Do | 2004 |
Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis.
Topics: Administration, Topical; Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Co | 2004 |
In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; DNA Gyrase; DNA Topoisomer | 2004 |
Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred B | 2004 |
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Ulcer; Disea | 2005 |
The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefazolin; Corneal Ulcer; Disease Mode | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantat | 2005 |
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Mi | 2005 |
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cornea; Disease Models, Animal; Eye Infections, Bacte | 2006 |
Prevention of Staphylococcus aureus endophthalmitis with topical gatifloxacin in a rabbit prophylaxis model.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Disease Models, Ani | 2006 |
Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Colony Count, Microbial; Corneal Ulcer; Dise | 2007 |
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Disease Model | 2007 |
Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Corneal Diseases; Disease Models, Animal; Epithelium, | 2007 |
Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Disease Models, Animal; Drug Carriers; Female; | 2007 |
Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Disease Models, Animal; DNA Topoisomerase IV; Ertapene | 2007 |
Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%.
Topics: Animals; Aza Compounds; Collagen Type IV; Cornea; Disease Models, Animal; Drug Evaluation, Preclinic | 2007 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulce | 2008 |
Toward improving therapeutic regimens for Bacillus endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Bacillus cereus; Biological Availability; Dexamethasone; Disease Mod | 2008 |
Prevention of endophthalmitis by collagen shields presoaked in fourth-generation fluoroquinolones versus by topical prophylaxis.
Topics: Administration, Topical; Animals; Anterior Chamber; Anti-Infective Agents; Collagen; Colony Count, M | 2008 |
In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
Topics: Animals; Anti-Infective Agents; Cell Death; Cricetinae; Disease Models, Animal; Erythromycin; Fluoro | 1994 |
Effect of 6-fluoro-8-methoxy quinolone (AM-1155) against chronic airway infection with Pseudomonas aeruginosa in a rat model.
Topics: Animals; Anti-Infective Agents; Chronic Disease; Ciprofloxacin; Disease Models, Animal; Fluoroquinol | 1997 |
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.
Topics: Animals; Anti-Infective Agents; Chlamydia; Chlamydia Infections; Chlamydia trachomatis; Chlamydophil | 1997 |
Efficacy of gatifloxacin alone and in combination with cefepime against penicillin-resistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro.
Topics: Animals; Anti-Infective Agents; Cefepime; Cephalosporins; Disease Models, Animal; Drug Therapy, Comb | 2001 |
Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Colony Count, Microbial; Disease Models, Animal; F | 2001 |
Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Disease Models, Animal; Fluoroquinolones; Gati | 2002 |